Skip to main content
Fig. 6 | Health Economics Review

Fig. 6

From: Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina

Fig. 6

Probability for sacubitril/valsartan of being accepted as cost-effective for a private payer. Value of ceiling ratio represents the range of cost-effectiveness thresholds. The curve represents the probability for sacubitril/valsartan of being Accepted as a cost-effective option, considering a range of cost-effectiveness thresholds. At (1 GDP per capita of 520,405.79 ARS the probability is 92%

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us